Health & Environmental Research Online (HERO)


Print Feedback Export to File
5080292 
Journal Article 
Low concentrations of perfluorooctane sulfonate repress osteogenic and enhance adipogenic differentiation of human mesenchymal stem cells 
Liu, W; Qin, H; Pan, Y; Luo, F; Zhang, Z 
2019 
Toxicology and Applied Pharmacology
ISSN: 0041-008X
EISSN: 1096-0333 
ACADEMIC PRESS INC ELSEVIER SCIENCE 
SAN DIEGO 
367 
82-91 
English 
Humans are exposed to perfluorooctane sulfonate (PFOS) from sources of both continuing discharges and environmental legacies, and the health effects of low dose exposure remain unknown. We assessed the effects of PFOS at 0.2-200 nmol/L on osteogenic and adipogenic differentiation of human bone marrow-derived mesenchymal stem cells (hBMSCs). PFOS affected hBMSCs differentiation in a nonmonotonic dose-response relationship, where the effects peaked at 100 nmol/L. PFOS repressed calcium deposition on day 14 of osteogenic differentiation. The molecular osteogenic biomarkers, osteopontin, osteonectin and osteocalcin, and the transcription factor β-catenin, were also decreased on differentiation day 7. In hBMSCs co-treated by PFOS and WNT signaling agonist, LiCl, the osteogenic marker levels were higher than those treated by PFOS alone. Moreover, the osteogenic effect of PFOS was repressed by DKK1, the WNT signaling antagonist. PFOS additionally supported the receptor activator of nuclear factor κB ligand/osteoprotegerin ratio. In contrast, PFOS enhanced adipogenesis in regard to lipid droplet formation and marker gene expression of PPARγ, CCAAT/enhancer-binding protein-α (C/EBPα), lipoprotein lipase and leptin. Microarray analysis identified 597 differentially expressed genes at p < .05 and log2 (fold change) > 0.3. These results demonstrated that PFOS repressed osteogenesis and enhanced adipogenesis, which could well explain the homeostatic imbalance seen in human bone associated with exposure to PFOS. 
Perfluoroalkyl compounds; Bone health; Stem cells; Multipotent differentiation; Microarray analysis 
PFAS
• Additional PFAS (formerly XAgency)
• Expanded PFAS SEM (formerly PFAS 430)
     Litsearch: September 2019
          PubMed
          Web of Science
     Not prioritized for screening
     Perfluorooctane
• PFAS 150
     Literature Search Update December 2020
          PubMed
          WOS
     Literature Search August 2019
          PubMed
          Web of Science
     Not prioritized for screening
     Perfluorooctane
     Perfluorooctanesulfonic acid
• PFOA (335-67-1) and PFOS (1763-23-1)
     Literature Search Update (2013-2019)
          PubMed
          WOS